Go Deep
Vor Biopharma Inc.
Vor Biopharma Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -19,316 | 0.1 | -5.63 | -0.02 | 1,815.15 |
| Oct 2026 | -19,224 | 0.1 | -5.54 | -0.02 | 1,780.27 |
| Oct 2026 | -19,594 | 0.1 | -5.71 | -0.02 | 1,836.55 |
| Oct 2026 | -19,191 | 0.1 | -5.33 | -0.02 | 1,707.71 |
| Oct 2026 | -19,280 | 0.1 | -5.33 | -0.02 | 1,710.49 |
| Oct 2026 | -19,592 | 0.1 | -5.62 | -0.02 | 1,804.36 |
| Oct 2026 | -19,751 | 0.1 | -5.60 | -0.02 | 1,791.39 |
| Oct 2026 | -19,751 | 0.1 | -5.60 | -0.02 | 1,787.76 |
Vor Biopharma Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -62,810,000.0 | -219,585,000.0 | 1,722,858,000.0 | -812,684,000.0 |
| EPS | -1.2 | -5.1 | — | -121.6 |
Vor Biopharma Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -695,981,000.0 | -116,914,000.0 | -117,863,000.0 | -92,094,000.0 | — |
| EPS | -70.5 | -34.0 | -35.0 | -46.6 | — |
Vor Biopharma Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 464,126,000.0 | 142,891,000.0 | 198,126,000.0 | 299,366,000.0 | — |
| Total Liabilities | 628,438,000.0 | 46,227,000.0 | 47,402,000.0 | 48,759,000.0 | — |
| Total Equity | -164,312,000.0 | 96,664,000.0 | 150,724,000.0 | 250,607,000.0 | — |
Owes vs Owns
Vor Biopharma Inc. owed $1.42 for every $1 it owned in Jun 2026, up from $0.16 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 1.42× | 1.35× | 0.32× | 0.24× | 0.16× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Vor Biopharma Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 98.1%Fixed assets (tangible) 0.7%Other assets 1.2%
How it's funded — Dec 2025
Payables 0.8%Other liabilities 98.7%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 455.2 | 91.9 | 137.2 | 230.2 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 3.5 | 41.6 | 50.1 | 57.1 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 5.4 | 9.4 | 10.9 | 12.0 |
| Liabilities & equity | ||||
| Short-term debt | 0.3 | 4.2 | 3.8 | 3.3 |
| Long-term debt | 2.7 | 27.6 | 31.8 | 35.6 |
| Payables | 5.1 | 1.5 | 0.8 | 1.8 |
| Other liabilities | 620.3 | 12.9 | 10.9 | 8.1 |
| Shareholders' equity | -164.3 | 96.7 | 150.7 | 250.6 |
| Net tangible assets | -164.3 | 96.7 | 150.7 | 250.6 |
Vor Biopharma Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -142,713,000.0 | -99,660,000.0 | -100,292,000.0 | -85,144,000.0 | — |
| Investing Activities | -48,802,000.0 | 96,857,000.0 | 71,008,000.0 | -94,091,000.0 | — |
| Financing Activities | 503,807,000.0 | 53,392,000.0 | 2,938,000.0 | 117,140,000.0 | — |